mutations, shed their negative result in people treated with VO. The sole factor that remained predictive of a shorter development-cost-free survival On this cohort of people was TP53This selection would be significantly precious for non-compliant patients or These in whom ibrutinib is contraindicated. If FCR may be the remedy of choice, warning ne